Protocol Ledger

NCT07142291 · Phase II · RECRUITING

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

Interventional Phase II clinical trial protocol NCT07142291 sponsored by PhenoNet in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-25 Enrollment: 105 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07142291
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)105 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07142291
Protocol FieldVerified Registry Value
NCT IdentifierNCT07142291
Consolidated Lead SponsorPhenoNet
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment105 participants (ESTIMATED)
Registered Start Date2025-11-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07142291
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
Mayo Clinic FloridaJacksonville, FLOpen Hospital Dossier ->
Fakultni nemocnice Hradec KraloveHradec Králové, CzechiaOpen Hospital Dossier ->
Hospital Universitario Vall d'HebronBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI